MARKET

SMMT

SMMT

Summit Therapeutics Inc
NASDAQ
13.66
-1.32
-8.81%
Pre Market: 13.84 +0.18 +1.31% 08:02 07/27 EDT
OPEN
13.72
PREV CLOSE
14.98
HIGH
14.42
LOW
13.20
VOLUME
304
TURNOVER
0
52 WEEK HIGH
30.98
52 WEEK LOW
12.55
MARKET CAP
10.90B
P/E (TTM)
-12.2051
1D
5D
1M
3M
1Y
5Y
1D
Clear Street Sticks to Its Buy Rating for Summit Therapeutics (SMMT)
TipRanks · 5h ago
Analysts Conflicted on These Healthcare Names: HCA Healthcare (HCA), Summit Therapeutics (SMMT) and Neuphoria Therapeutics (NEUP)
TipRanks · 6h ago
Weekly Report: what happened at SMMT last week (0720-0724)?
Weekly Report · 8h ago
Summit Therapeutics Faces Serious Going-Concern Risk as Cash Shortfall Threatens Operations
TipRanks · 2d ago
Noteworthy Friday Option Activity: SAFT, SMMT, ADBE
NASDAQ · 2d ago
Arcus: 'Buy' On Casdatifan Late-Stage CcRCC Advancement And 1st-Line Expansions
Seeking Alpha · 2d ago
BUZZ-U.S. STOCKS ON THE MOVE-Tenet, SLB, Digital Realty
Reuters · 2d ago
Summit Therapeutics price target lowered to $15 from $17 at Jefferies
TipRanks · 2d ago
More
About SMMT
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.

Webull offers Summit Therapeutics Inc stock information, including NASDAQ: SMMT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SMMT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SMMT stock methods without spending real money on the virtual paper trading platform.